CellTivity Scientific

Executive Summary

CellTivity Scientific is a French-American biotechnology company pioneering real-time metabolic imaging diagnostics to enhance cancer biopsy assessment. Its flagship Van Gogh™ platform leverages Dynamic Cell Imaging (DCI) to generate metabolic 'heat maps' of biopsy samples, enabling rapid and accurate adequacy evaluation at the point of care. Initially targeting lung cancer detection via procedures such as EBUS and robotic bronchoscopy, the technology aims to reduce repeat biopsies and improve diagnostic yields. Founded in 2015 and headquartered in Lyon, France, CellTivity operates in the cell therapy and regenerative medicine space, though its core focus is on diagnostic imaging. The company is privately held and has not disclosed funding rounds or valuation, indicating an early-stage profile. Its innovation addresses a critical unmet need in oncology pathology, but the lack of public clinical data or regulatory milestones suggests the technology is still in development or early commercialization phases. If successful, Van Gogh™ could become a standard adjunct in interventional pulmonology, improving patient outcomes and procedural efficiency.

Upcoming Catalysts (preview)

• Q4 2026Completion of first pivotal clinical study for Van Gogh™ in lung cancer60% success
• Q2 2027FDA 510(k) clearance or CE marking submission40% success
• Q1 2027Strategic partnership with a major bronchoscopy device manufacturer50% success